epoetin alfa
- Generic Name
- epoetin alfa
A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.
Phase 2
Completed
- Conditions
- Orthopedic ProceduresCardiovascular Surgical ProceduresMammaplastyBlood TransfusionBlood Transfusion, AutologousOrthopedic Surgery
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-05-18
- Target Recruit Count
- 112
- Registration Number
- NCT00270023
A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer
Phase 2
Completed
- Conditions
- Anemia
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 56
- Registration Number
- NCT00269984
The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma
Phase 3
Completed
- Conditions
- AnemiaMultiple Myeloma
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-05-18
- Target Recruit Count
- 156
- Registration Number
- NCT00270101
A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.
Phase 3
Withdrawn
- Conditions
- Blood TransfusionOrthopedic SurgeryAnemia
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Janssen-Ortho Inc., Canada
- Registration Number
- NCT00269971
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy
Phase 2
Completed
- Conditions
- AnemiaNeoplasms
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2011-05-18
- Target Recruit Count
- 86
- Registration Number
- NCT00266617
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 492
- Registration Number
- NCT00264108
A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients
Phase 3
Completed
- Conditions
- Kidney Failure, ChronicAnemia
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2010-12-03
- Target Recruit Count
- 596
- Registration Number
- NCT00261521
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
Phase 3
Completed
- Conditions
- AnemiaHodgkin DiseaseLeukemiaLymphoma, Non-hodgkin
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 224
- Registration Number
- NCT00261677
A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer
Phase 3
Terminated
- Conditions
- AnemiaBreast NeoplasmsHemoglobinsQuality of LifeChemotherapy, Adjuvant
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Ortho Biotech Products, L.P.
- Target Recruit Count
- 37
- Registration Number
- NCT00246597
A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients
Phase 2
Terminated
- Conditions
- AnemiaHIV
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 31
- Registration Number
- NCT00246298
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath